J Clin Aesthet Dermatol. 2020;13(10):45–48 by James Q. Del Rosso, DO, FAAD, FAOCD Dr. Del Rosso is Research Director at JDR Dermatology Research in Las Vegas, Nevada, is with Thomas Dermatology in Las Vegas, Nevada, and is an adjunct clinical professor of dermatology at Touro University Nevada in Henderson, Nevada. FUNDING: No funding was provided
J Clin Aesthet Dermatol. 2020;13(9):26–32 by Hilary Baldwin, MD Dr. Baldwin is the Medical Director of the Acne Treatment and Research Center in Brooklyn, New York and is with Rutgers Robert Wood Johnson Medical Center in New Brunswick, New Jersey. ABSTRACT: Acne vulgaris is the most common dermatological disease in the United States, affecting up
Objective. We sought to evaluate the safety, tolerability, and patterns of use for the once-daily oral, narrow-spectrum antibiotic sarecycline in patients with moderate-to-severe acne vulgaris during a 40-week Phase III, multicenter, open-label extension study.